Glial fibrillary acidic protein (GFAP) is an intermediate filament protein specifically expressed in astrocytes in the CNS. To examine the function of GFAP in vivo, the Gfap gene was disrupted by gene targeting in embryonic stem cells. Mice homozygous for the mutation were completely devoid of GFAP but exhibited normal development and showed no obvious anatomical abnormalities in the CNS. When inoculated with infectious scrapie prions, the mutant mice exhibited neuropathological changes typical of prion diseases. Infectious prions accumulated in brains of the mutant mice to a degree similar to that in control littermates. These results suggest that GFAP is not essential for the morphogenesis of the CNS or for astrocyUc responses against neuronal injury. The results argue against the hypothesis that GFAP plays a crucial role in the pathogenesis of prion diseases.
Introduction
Intermediate filament (IF) proteins are prominent components of the cytoskeleton and nuclear envelope of most eukaryotic cell types. IF proteins constitute an extremely large multigene family and are classified into the distinct sequence types I-V (for review, see Steinert and Roop, 1988) . The expression of IF proteins exhibits a high degree of cell-type specificity, such as keratins of types I and II in epithelial cells, neurofilaments of type IV in nerve cells, desmin of type III in muscle cells, vimentin of type III in various mesenchymal cells, and glial fibrillary acidic protein (GFAP) of type III in astrocytes (for a review, see Steinert and Roop, 1988) . The differential expression of IF proteins in different cell types implies that they have specialized roles in the differentiation and function of these cells. The following evidence supports this concept. Injection of antibodies against neurofilament-M subunit into Xenopus laevis embryos inhibits development of peripheral nerve cells (Szaro et al., 1991) . Transgenic mice that accumulate neu rofilament-L subunit exhibit axonal degeneration and severe skeletal muscle atrophy (Xu et al., 1993) . A mutant strain of the Japanese quail, quiver, which lacks neurofilaments, has the clinical feature of generalized quivering and the morphological feature of decrease in size of myelinated axons (Yamasaki et al., 1991) . Keratin depletion in Xenopus embryos by either antisense oligonucleotides or antibody injection prevents gastrulation (Klymkowsky et al., 1983; Torpey et al., 1992) . Transgenic mice expressing a dominant-negative form of keratin 14 suffered from skin abnormalities resembling a human genetic disease (Vassar et al., 1991) . A null mutation in the keratin 8 gene, which is first expressed together with keratin 18 during embryogenesis, causes mid-gestational lethality in mice (Baribault et al., 1993) .
Astrocytes fill the interstices between neuronal cell bodies and extend processes to ensheathe axons and blood vessels (Peters et al., 1991) . Astrocytes are believed to be crucial for the nutritional and structural support of neurons and for the regulation of local concentrations of neurotransmitters and ions. Other studies suggest that astrocytes have an inductive role in the formation of tight junctions between brain endothelia (Janzer and Raff, 1987; Arthur et al., 1987) , contributing to the establishment of the bloodbrain barrier (BBB) in vivo. The function of GFAP in astrocytes is largely unknown. Interestingly, removal of GFAP in a human astrocytoma cell line by transfection with an antisense construct caused an impaired ability of the cells to extend glial processes upon neuronal induction (Wei nstein et al., 1991) , suggesting the necessity of GFAP for the formation of stable astrocytic processes in response to neurons. During development of the CNS, neurons are born on the ventricular surface of the neural tube and appear to migrate to their final destination along astrocytic processes (Rakic, 1972 (Rakic, , 1981 . Thus, it is predicted that structural support of astrocytic processes by GFAP may be critical for the morphogenesis of the CNS.
Astrocytes show remarkable cellular responses to a wide range of pathological conditions of the CNS. Astrocyte swelling, the Alzheimer type II response, and reactive astrocytosis (reactive gliosis) are examples of common astrocytic changes (for review, see Norenberg, 1994) . Reactive astrocytes are characterized histologically by cytoplasmic hypertrophy associated with profusion of long and thick processes filled with GFAP, and by often enlarged and irregularly outlined nuclei. The astroglial scarring that frequently occurs under pathological conditions has also been interpreted as a process of repair and regeneration of the CNS (for review, see Reier and Houle, 1988) . The hallmark of reactive astrocytosis is a prominent accumulation of GFAP (Eng, 1988) .
Prion diseases, such as scrapie in animals and Creutzfeldt-Jakob disease in humans, are transmissible neurodegenerative disorders (spongiform encephalopathy) that cause typical reactive astrocytosis (Mackenzie, 1983; Weitgrefe et al., 1985; Manuelidis et al., 1987; BL~eler et al., 1993) . Thus, it is important to determine whether GFAP has a role in the pathogenesis of prion diseases. S. B. Prusiner proposed the "protein only" hypothesis in which the prion, the infectious agent, is PrP s°, a modified form of the normal host protein PrP c (Prusiner, 1982) . Propagation of the prion is ascribed to the conversion of PrP c into PrP s° under the influence of PrP s~ (Prusiner, 1991) . This hypothesis has been confirmed directly by experiments utilizing mice devoid of PrP c generated by gene targeting (BLieler et al., 1993) and by experiments based on an in vitro cell-free system (Kocisko et al., 1994) . However, it is not known whether any other molecule participates in either propagation of PrP s° or progression of the disease. Intriguing relationships between GFAP and infectious prions have been observed. The progression of prion disease causes a typical reactive ast rocytosis along with increased GFAP expression (Weitgrefe et al., 1985; Manuelidis et al., 1987; B~eler et al., 1993) . It has been suggested that high local concentrations of infectious Creutzfeldt-Jakob disease prion correlate with the level of Gfap mRNA expression in astrocytes, rather than with the severity of the neuronal degeneration (Manuelidis et al., 1987) . Moreover, biochemical studies have revealed the specific binding of PrP s~ to GFAP (Oesch et al., 1990) . In this context, it is noteworthy that the conversion of PrP c to PrP s° and the accumulation of PrP s~ in astrocytes precede PrP s~ conversion and accumulation in neurons in the course of the disease (Diedrich et al., 1991) . These observations suggested a potential role for GFAP in the pathogenesis of prion diseases.
To address the function of GFAP in vivo, we used gene targeting to generate mutant mice in which the Gfap gene was disrupted by replacing it with the lacZ gene (Capecchi, 1989) . Our specific goals were to determine whether GFAP is crucial for the development of the CNS and whether GFAP participates in the pathogenesis of scrapie-induced encephalopathy.
Results

The Mutation of the Gfap Locus
To generate a nu II mutation in the Gfap gene, we disrupted the first exon of the gene by gene targeting in embryonic stem (ES) cells. The targeting vector contains 5.5 kb of homologous sequences from the Gfap gene locus. The pgk-neo (McBurney et al., 1991) and MC1-DT-A (Yagi et al., 1990 ) gene cassettes were used as positive and negative selection markers, respectively ( Figure 1A ). The promoterless/acZ, a reporter gene, was inserted just downstream of the initiation codon of the Gfap gene in the sense orientation. Following homologous integration, this construct should express/acZ only at sites where the Gfap gene is normally transcriptionally active. The targeting vector was transfected into E14 ES cells (Hooper et al., 1987) by electroporation. Of the 232 ES clones analyzed, 25 were found to have the targeted mutation. Cells from 5 clones were injected into C57BL/6J blastocysts; 3 clones gave rise to germline chimeras. Intercrosses between the heterozygotes (Gfap +j-) gave rise to homozygotes (Gfap+), Gfap +/-, and wild types (Gfap ÷l+) at grow up normally and are healthy at least up to the age that we have studied them (14 months). Both male and female Gfap -/-mice are fertile. To confirm that the mutation introduced into the Gfap gene abolishes GFAP synthesis, littermates were subjected to Northern, immunoblot, and immunohistochemical analyses. Northern analysis detected no Gfap mRNA in the brain of Gfap -/-mice (data not shown). Immunoblot analysis of lysates from cerebrum, cerebellum, and spinal cord demonstrated the absence of GFAP in Gfap -/-mice and a reduced level of GFAP in Gfap +/-mice compared with Gfap +/+ mice ( Figure 1C ). Representative data of immunohistochemical analysis are shown in Figure 2 . Staining with anti-GFAP monoclonal antibody displayed the typical pattern of astrocytes in the brains of Gfap +/÷ mice ( Figure 2B ), whereas no staining was observed in Gfap -lmice ( Figure 2A ). The data represented were obtained with a monoclonal antibody (GF12.24). Similar results were also obtained by using another monoclonal (6F2) and rabbit polyclonal antibodies in both immunoblot and immunohistochemical analyses. These results clearly demonstrate the complete lack of GFAP in the Gfap -/-mice.
Development of Astrocytes Devoid of GFAP
To analyze the development of astrocytes in the mutant mice lacking GFAP, we ontogenetically followed the expression of lacZ in the mutant mice. Several studies have shown that GFAP is first detectable during late embryonic development and that its immunoreactivity increases postnatally (Sapirstein, 1983; Weir et al., 1984) . Whole-mount lacZ staining was performed on entire embryos from days 12.5 to 18.5 postcoitus. For postnatal 7-, 15-, and 20-dayold and 6-week-old mice, the brain and spinal cord were stained. As shown in Figure 3 , lacZ expression was first detected in the paraventricular regions of the lateral, third, and fourth ventricles on embryonic day (ED) 17.5 ( Figure  3A ). At ED 18.5, the optic nerve, medulla oblongata, and spinal cord expressed lacZ ( Figure 3B ). After birth, lacZ was expressed in many other regions of the brain, with strong expression in the pia mater, optic nerve, corpus callosum, medulla oblongata, spinal cord, and cerebellar white matter ( Figures 3C and 3D ). 15-Galactosidase activity declined in the brains of adult mice. The expression pattern correlated well with that of GFAP in Gfap +/-mice (data not shown), indicating the usefulness of I~-galactosidase activity as a marker for GFAP-deficient astrocytes. However, 13-galactosidase activity was slightly detectable by microscopy in cells scattered in most parenchymal regions. This seemed to be caused by diffusion of low amounts of I~-galactosidase while preparing sections. When the mice were treated with kainic acid, 13-galactosidase activity was strongly induced in mutant astrocytes, particularly in the hippocampus. Some cells expressing 13-galactosidase surrounded the capillaries ( Figure 2C ), as normal astrocytes do ( Figure 2D ). Staining with an antibody against S-100, another marker protein for astrocytes ( Ludwin et al., 1976) , also revealed that the distribution of the mutant astrocytes was similar to that of normal astrocytes ( Figure 2E and 2F). Bergmann glia in the cerebellum, which express vimentin as well as GFAP in Gfap ÷~÷ mice, were also stained with anti-vimentin antibody in Gfap + mice. The shape and immunoreactivity of the processes of mutant Bergmann glia did not seem to be altered ( Figures 2G and 2H ). These results suggest that the development and localization of astrocytes are not significantly hampered by the lack of GFAP.
No Evidence for Compensatory Expression of Abnormal IF Proteins in Astrocytes
of Gfap + Mice To determine whether some other IF proteins are synthesized to take the place of GFAP in the mutant astrocytes, we analyzed cytosketetal proteins, which are insoluble in nonionic solvent (Triton X-100), isolated from the optic nerves and whole brains of Gfap -/-mice by SDS-polyacrylamide gel electrophoresis (SDS-PAGE; Figure 4 ). The optic nerve is the tissue with the highest abundance of astrocytes. A Triton-insoluble fraction from optic nerve of Gfap +~÷ mice contained the neurofilament triplets (200 kDa NF, 145 kDa NF, and 68 kDa NF), 57 kDa vimentin, and 60 kDa GFAP. The identities of these proteins were confirmed by immunoblot analysis (data not shown). In addition to these proteins, a protein of 62 kDa was detected. The identity of this molecule is not yet clear; however, amino acid analysis indicated a similarity to the fourth neurofilament of 66 kDa identified in rat (Chiu et al., 1989 ; data not shown). This protein was hardly detectable in cultured astrocytes (data not shown), suggesting that it is specific to neurons. The fraction from Gfap -~-mice contained all of these proteins except GFAP. Several faint bands were observed in addition to molecules described above, but we did not observe quantitative differences in any proteins between mutant and wild-type fractions analyzed. Similar results were obtained with whole-brain extracts ( Figure 4) . Consistently, anti-cytokeratins and anti-desmin antibodies showed no immunoreactivity in astrocytes of mutant mice. Together, these results render it unlikely that the lack of GFAP leads to the compensatory expression of alternative IF protein(s) in astrocytes of Gfap + mice.
Normal Development of CNS in Gfap + Mice
Several lines of evidence from in vitro studies have suggested direct interactions between neurons and astrocytes. Furthermore, both cell types develop from a common progenitor. Therefore, the mutation of Gfap may alter the development of neurons. However, we found no apparent histological differences in brain architecture between Gfap + mutant and wild-type mice. Immunohistology with antibodies against actin, c(-tubulin, neurofilaments, microtubule-associated protein 1 (MAP1), neural cell adhesion molecule (N-CAM), and CNPase also failed to reveal any detectable abnormality (data not shown). Cell numbers in tempolateral cortex and thalamus counted at different ages (15-day-old and 6-, 16-, and 36-week-old) were similar in Gfap -~-and Gfap +/+ mice (data not shown).
To evaluate the function of BBB, peroxidase trace experiments (Reese and Karnovsky, 1967) were performed in Gfap -/-mutant and Gfap÷/+mice. Horseradish peroxidase or microperoxidase was injected intravenously, and the brains were subsequently fixed and sliced. Then, the extravasation of peroxidase was detected by diaminobenzidine reaction. No leakage of peroxidase was observed with light or electron microscopic analysis in the brains of Gfap -/-mutant mice (data not shown), except for the regions in which leakage is commonly observed in the normal brain, such as the paraventricular region of the third ventricle. This result suggests that deficiency of GFAP in astrocytes does not interfere with the establishment and maintenance of the BBB.
From these results, it appears that the Gfap gene is not (Shinagawa et al., 1985) . Parentheses indicate the number of mice inoculated with extract from brains of normal mice as a mock inoculation. b Minus sign indicates no appearance of disease during the observation period. c Minus sign indicates that all mice survived during the observation period. The titers in brains recovered at 2, 12, and 20 weeks after inoculation (wks) were determined according to the procedure described by Prusiner et al. (1982) . d One of 5 mice inoculated developed symptoms at 290 days. One of 5 mice inoculated developed symptoms at 220 days. ND, not determined.
essential for the development and basic functions of the murine CNS.
Inoculation of Scrapie Prion (PrP sc) in Gfap + Mutant Mice
Gfap -/-, Gfap +/-, and Gfap ÷/÷ mice (7-to 8-week-old) were inoculated intracerebrally with a dose (102.8 LDso per animal) of mouse-adapted Obihiro strain of scrapie prion (prps°; Shinagawa et al., 1985) . The genetic background of Gfap -/-, Gfap +/-, and Gfap +/+ mice is derived from 129/ Ola and C57BL/6J strains. The 129 and C57BL/6 strains have the haplotype a of priori protein gene (Prn-p a) alleles, which causes a short scrapie incubation period (Carlson et al., 1988) . As a control, ICR/SIc mice, a strain used for the determination of prion titer, were inoculated with PrP so. The mice were sacrificed at 2, 12, 20, and 23 weeks after inoculation for histological and biochemical analyses. As a control, mice mock-infected with lysates from normal mouse brains were also examined in the same manner (Table 1) . ICR/SIc mice first showed typical neurological symptoms at 143 days of inoculation and died at 176 _.+ 2 days. Similarly, Gfap -/-, Gfap ÷/-, and Gfap +/+ mice first showed the neurological symptoms at 143-153 days and died at 175 _ 2, 172 -4-3, and 173 -4-4days, respectively (Table  1) . No striking differences were observed in the neurological symptoms displayed by these three different genotypes.
For the detection of scrapie prion (prpsc), extracts were prepared from brains of infected mice, and immunoblotting was performed using polyclonal anti-prion protein (PrP) antiserum obtained by immunization of a rabbit against a synthetic peptide corresponding to amino acids 213-226 of mouse PrP (Yokoyama et al., unpublished data) . The proteinase K-resistant PrP sc was detected in all mouse brain extracts 20 weeks after inoculation (data not shown). For the immunohistochemical detection of PrP amyloid plaques, tissue sections were stained with the above antibody. PrP amyloid plaques were found in various regions of the brain, such as the cerebral cortex, corpus callosum, hippocampus, and thalamus, both in scrapie-infected Gfap -/-and Gfap +/÷ mice ( Figures 5A and 5B). No plaques were observed in mock-infected brains.
At 2, 12, and 20 weeks after inoculation, brains from 2-4 mice were sampled and used for the infectivity titration assay. The samples were homogenized in phosphatebuffered saline (PBS), and a pool of the extracts was inoculated intracerebrally into 5-7 ICR/SIc mice per group. Significant propagation of infectious units was detected in Gfap -/-mice as well as Gfap +/-and Gfap +/+ mice by 12 weeks of inoculation (Table 1) . We did not observe significant differences in infectivities from the three genotypes.
These data reveal that GFAP-deficient mice are as susceptible to scrapie prion as normal mice, and that GFAP molecules do not significantly affect the propagation of PrP sc in the brain of mice.
Astrocytic Responses in Scrapie-lnfected Gfap -l-
Mutant Mice
To evaluate the scrapie-induced neuropathology, brains of scrapie-infected and mock-infected Gfap -/-and Gfap +~÷ mice were analyzed histologically. Both scrapie-infected Gfap -/-and Gfap +/÷ mice showed vacuolative changes (spongiform degeneration typical of scrapie encephalopathy) in the cortex ( Figures 5E and 5F ), hippocampus (Figures 51 and 5J) , and thalamus (data not shown) at 20 and 23 weeks after infection. Scrapie-infected Gfap ÷/+ mice showed remarkable reactive astrocytosis as detected by immunostaining with an anti-GFAP antibody ( Figures 5F  and 5J ). Since the same staining gave rise to no signal in Gfap -/-mice ( Figures 5E and 51) , the reactive response of mutant astrocytes in Gfap -/-mice was evaluated by lacZ staining. Figure 6 shows 13-galactosidase activities in the brains of scrapie-infected and mock-infected Gfap -/-mice at 2, 12, 20, and 23 weeks after inoculation. A significant induction of 13-galactosidase activity was first observed at 12 weeks after infection (in hippocampus and thalamus; Figure 6 , arrows), and the activity increased dramatically by 23 weeks after infection (Figures 5E and 51; Figure 6 ).
Vimentin is known to be expressed in reactive astrocytes Gfap -/-mutant (A, C, E, G, and I) and Gfap +/* (B, D, F, H, and J) mice at 23 weeks after inoculation. PrP amyloid plaques in the cerebral cortex of Gfap/-(A) and Gfap +/÷ (B). Peroxidase immunohistochemistry was performed with an antiserum obtained by immunization of rabbit with the synthetic peptide that corresponds to amino acids 213-226 of mouse PrP. Double staining for GFAP and 13-galactosidase was performed on the tempolateral cortex of cerebrum (C-F) and CA1 region of hippocampus (G--J). The vacuolative changes were observed in the cortex and hippocampus of scrapie-infected Gfap ÷ and Gfap */* mice (E, F, I, and J). In mock-infected Gfap +/÷ mice, scattered astrocytes with slender GFAP-positive processes are observed (D and H), whereas numerous reactive astrocytes with hypertrophic cytoplasm and strongly GFAP-positive processes were observed in scrapie-infected Gfap +/+ mice (F and J). In Gfap -/-mice, an increased expression of lacZ in the cortex and hippocampus occurs in scrapie-infected (E and I) brain. No GFAP immunoreactivity was detected in mock-infected (C and G) or scrapie-infected (E and I) brains from mutant mice. The sections were lightly counterstained with hematoxylin. Bars, 50 ~tm (A and B), 100 ~m (C-H). Mock-infected (Mock) and scrapie-infected (Scrapie) brains at 2, 12, 20, and 23 weeks after inoculation are aligned in the left and right columns, respectively. Increased lacZ expression was first evident in the hippocampus and thalamus 12 weeks after infection (indicated by arrows). By 23 weeks after scrapie infection, the 13-galactosidase activity had increased dramatically in a wide area of the brain regions. (Dahl et al., 1981; Pixley and de Vellis, 1984; Schiffer et al.,1986; Petito et al., 1990) , in contrast to most astrocytes under physiological conditions. Therefore, we analyzed the astrocytic reactivity in scrapie-infected Gfap -/-mice by vimentin immunocytochemistry. Moderate vimentin immunoreactivity was observed in the cytoplasm of reactive astrocytes of scrapie-infected Gfap +/÷ mice ( Figure 7A ). Immunoreactivity against S-100 protein, a marker for astrocytes, was also detected in reactive astrocytes of scrapie-infected Gfap ÷/+ mice ( Figure 7C ). In Gfap -/-mice, 13-galactosidase-positive mutant astrocytes were colabeled with anti-vimentin and anti-S-100 antibodies (Figures 7E and 7F) , indicating their astrocytic identity. However, the immunostaining of vimentin and S-100 protein in Figure 7A ). In contrast, vimentin signals in mutant astrocytes tend to be granular and scarce around the nuclei ( Figure 7B ). S-100 protein is normally localized to the nuclei and cytoplasm of reactive astrocytes ( Figure  7C ). The anti-S-100 antibody strongly stained the nuclei of the astrocytes of Gfap -~-( Figure 7D ) as well as Gfap +~+ mice. However, similar to anti-vimentin staining, S-100 signals are scarce in the cytoplasm of mutant astrocytes, particularly around the nuclei ( Figure 7D ). In agreement with the immunohistochemistry, immunoblot analysis clearly showed an increase of GFAP and vimentin in the brains of scrapie-infected Gfap ÷~÷ mice 20 weeks after inoculation. In the brains of scrapie-infected Gfap -~-mice, increased vimentin expression was also detected by immunoblotting (data not shown).
These results show that scrapie-specific neuropathology is induced in the brain of Gfap-~-mice. Furthermore, they suggest that GFAP is not essential for the induction of reactive astrocytosis.
Discussion
In the present study, we disrupted the Gfap gene in mice by replacing a short fragment of the first exon with the lacZ gene using ES cell technology. GFAP expression in astrocytes is thought to be important for the morphogenesis and structural support of the CNS. However, mutant mice devoid of GFAP exhibit no obvious defects in development and tissue architecture in the CNS. Astrocytes lacking GFAP have a normal distribution, and the mutation did not result in any detectable deficiency of neuronal development. Additionally, the mutant astrocytes extend their processes to capillaries as normal cells do. Electron microscopic analysis and peroxidase permeability tests showed that the BBB is structurally normal in Gfap -I-mutant mice (data not shown).
The lack of any apparent defects in the mutant mice suggests that GFAP does not have an essential role in the development of astrocytes. Astrocytes are known to be heterogeneous in cell shape and probably in function. Some astrocytes do not contain detectable amounts of GFAP in vivo. Given the fact that the null mutation in the Gfap gene does not induce compensatory expression of alternative IF proteins the data may suggest that no IF proteins are required for the physiology of some types of astrocytes. Very recently, vimentin knockout mice were generated (Colucci-Guyon et al., 1994) . The mice devoid of vimentin have not shown any apparent defects. As in the case of GFAP, there was no evidence for the compensatory expression of alternative IF proteins in the vimentindeficient mice, and a complete lack of any IF networks in vivo was observed in the lens fibers from these mutant mice.
Even though the above interpretation is true for some astrocytes, it is also possible that some other molecule(s) functionally compensate for the lack of GFAP. In the course of astrocyte development, a transition in expression of IF protein genes has been observed (Hockfield and McKay, 1985; Lendahl et al., 1990; Fliegner and Liem, 1991 ; Liem, 1993) . Proliferating neuroepithelial stem cells, which can differentiate into neurons and glia, express vi- Vimentin immunoreactivity is shown in the cytoplasm (A), whereas S-100 immunoreactivity is located in both the cytoplasm and the nucleus (C) of reactive astrocytes in Gfap +~÷ mice. Please note in Gfap -~-mice, vimentin immunoreactivity is granular (B), and S-100 immunoreactivity is strong in the nucleus but not in the cytoplasm (D). In Gfap-"-mice, lacZ-expressing cells show vimentin (E) and S-100 (F) immunoreactivities (arrows). The sections were lightly counterstained with hematoxylin. Bars, 20 p.m (A-D), 25 ~m (E and F). mentin and nestin (Frederiksen and McKay, 1988; Lendahl et al., 1990) . Radial glial cells that differentiate into CNS astrocytes (Schmechel and Rakic, 1979) express both vimentin and nestin (Hockfield and McKay, 1985) . GFAPnegative and vimentin-positive radial glia of rat disappear at an early postnatal stage, whereas the expression of GFAP in mature astrocytes dramatically increases between birth and postnatal day 20 (Pixley and de Vellis, 1984) . Nestin is absent in astrocytes from adult brain, whereas vimentin is constitutively expressed in some mature astrocytes, such as the astrocytes in the optic nerve, Bergmann glial cells in cerebellum, and white matter astrocytes in the adult brain (Schnitzer et al., 1981; Yokoyama et al., 1981; Pixley et al., 1984; Pixley and de Vellis, 1984) . Furthermore, vimentin is induced in reactive astrocytes following neuronal damage (Dahl et al, 1981; Pixley and de Vellis, 1984; Schiffer et al., 1986; Petito et al., 1990) and in in vitro-cultured astrocytes, suggesting that the Vim locus is not completely silent in mature astrocytes, in which vimentin is hardly detectable in vivo. Therefore, vimentin may in part compensate for the lack of GFAP. Very small amounts of vimentin could be sufficient for the putative functional compensation. The hypothesis discussed above should be tested by generating double knockout mice for GFAP and vimentin.
Since the IF proteins comprise a very large gene family, more unidentified IF proteins may be involved in the putative compensation. Indeed, a monoclonal antibody (34C9) that reacts with an epitope of human epidermal keratin has been demonstrated to bind to a cytoskeletal fiber structure closely associated with GFAP in a subclass of astrocytes of the adult hamster brain and in astrocytes in fetal mouse brain cultures (Franko et al., 1987) . In immunoblot analysis, the 34C9 monoclonal antibody was shown to recognize a 65 kDa protein (p65) and not to recognize GFAP. This observation suggests that epidermal keratins share an epitope not only among themselves but also with a keratin in neuronal tissue. The p65 might be a restricted IF protein that copolymerizes with GFAP. Alternatively, it could be an IF-associated protein. This protein is another candidate molecule that may compensate for the lack of GFAP.
GFAP accumulation in reactive astrocytes has been observed in scrapie-infected brain (Mackenzie, 1983; Wietgrefe et al., 1985; Kretzschmar et al., 1986; B0e!er et al., 1993) and human brain with Creutzfeldt-Jakob disease (Hirano et al., 1972) . Interestingly, previous biochemical studies by Oesch et al. (1990) showed a high affinity of PrP s° or its cellular form, PrP c, to GFAP. It was therefore important to determine whether GFAP has a role in the pathogenesis of prion diseases. In this study, Gfap -/-mice infected with PrP s~ showed the same scrapie-specific neuropathology and the same disease time course as did scrapie-infected Gfap +/÷ mice. Our results revealed that Gfap -/-mice have a normal susceptibility to scrapie infection and are unaffected in the propagation of PrP sc. These results indicate that GFAP is not crucial for scrapieinduced neuropathogenesis. However, we cannot exclude the possibility that the interaction between GFAP and PrP c is physiologically required for astrocytic functions, and in turn for some neuronal activities. PrP c mRNA and protein, abundantly expressed in neurons, have been detected in many cell types, including astrocytes (Kretzschmar et al., 1986; DeArmond et al., 1987; Brown et al., 1990; Cashman et al., 1990) . Interestingly, it has been shown recently that hippocampal slices from PrP null mutant mice have weakened y-aminobutyric acid type A receptor-mediated fast inhibition and impaired long-term potentiation (Collinge et al., 1994) . The remaining issue could be tested by analyzing the cumulative effects on these activities in double knockout mice for GFAP and PrP.
The scrapie prion is known to be a strong inducer of reactive astrocytes. The progression of the prion diseases results in typical reactive astrocytosis. The reactive astrocytes are histologically characterized by cytoplasmic hypertrophy associated with profusion of long and thick processes filled with GFAP, and often by enlarged and irregularly outlined nuclei. Astrocytes devoid of GFAP in Gfap -/-mutant mice showed increased lacZ expression along with the progression of disease, correlating with accumulation of GFAP in wild-type mice. Increased expression of vimentin was also detected in the astrocytes of mutant as well as wild-type mice by immunoblot and immunocytochemical analysis. These results suggest that the astrocytes devoid of GFAP are able to be transformed to a reactive state, and that the 13-galactosidase activity in the mutant astrocytes is a useful marker for the reactive state. The 13-galactosidase activity may reflect the Gfap gene transcriptional activity better than the level of GFAP protein itself, whose stability could be altered by polymerization. Therefore, the mutant mice generated here may provide a useful tool to analyze the induction mechanisms for reactive responses of astrocytes.
The mutant astrocytes from scrapie-infected mice showed subtle differences from wild-type reactive astrocytes in stainability with anti-S-100 and anti-vimentin antibodies. The mutant astrocytes did not seem to have the normal cytoplasmic localization of these molecules. S-100 protein, which is a calcium-binding, glial-specific protein, is known to bind to GFAP and prohibit its polymerization in vitro (Bianchi et al., 1993) . Vimentin is known to copolymerize with GFAP (Quinlan and Franke, 1983; Wang et al., 1984) . Therefore, it is not surprising that the lack of GFAP might have altered the subcellular localization and/or polymerization of these molecules. The consequences of these observations are not yet known. However, if the subcellular distribution of these and other molecules were altered in astrocytes under normal physiological conditions, the mutation might alter the physiological functions specific for astrocytes. Additional electrophysiological and biochemical studies are required to analyze this issue further.
Experimental Procedures
Construction of the Targeting Vector
A genomic DNA clone of mouse GFAP was isolated from a 129/Sv genomic library by screening with a mouse DNA fragment previously amplified by polymerase chain reaction. The fragments used were a 2.0 kb SaU fragment of the promoter region, a 3.5 kb Sacl fragment from exon 1 to intron 1, a 3.7 kb HindllI-BamHI lacZ gene fragment prepared from pCH110 (Pharmacia), a 1.8 kb pgk-neo gene cassette derived from pKJ 1 (McBurney et al., 1991; a gift from Michael A. Rudnicki) , and a 1.0 kb XhoI-Sall diphtheria toxin A-fragment (DT-A) gene cassette derived from pMC1DT-A (Yagi et al., 1990 ; a gift of Shinichi Aizawa). The resulting construct could transcribe the lacZ gene from the GFAP promoter and abolish the transcription of the Gfap gene.
Targeting Experiments
The ES cell line used was E14 (Hooper et al., 1987) . Cell culture and the targeting experiment were carried out as described previously (Itohara et al., 1993) . In brief, 5 x 107 ES cells were electroporated with a Bio-Rad Gene Pulser (800 V and 3 mF in a 0.4 cm electrode distance) using 30 p.g of DNA. Prior to electroporation, the targeting vector was linearized by digestion with Notl. The electroporated cells were plated in ten 10 cm dishes coated with mitotically inactivated embryonic fibroblasts derived from the TCR 8 gene knockout mice (Itohara et al., 1993) . G4t8 was added 24 hr after electroporation, and colonies were picked at day 7 of selection into wells of 96-well plates. The cells were cultured and passaged into 24-well plates, and half of the cells were stored in liquid nitrogen until the completion of screen-ing. The other half of the cells were screened by digestion with Sacl or BamHI and hybridization with a 5' external probe (5' probe; a 0.5 kb SacI-Ball fragment) or a 3'external probe (3'probe; a 0.4 kb HindlllBamHI fragment). Southern blots were analyzed using a Fujix BioImage Analyzer BAS2000.
Generation of Chimeric Mice and Screening of Mutant Mice
Chimeras were generated as described (Bradley, 1987) . ES cells (15) (16) (17) (18) (19) (20) were microinjected into C57BL/6J blastocysts at 3.5 days postcoitum. After injection, the embryos were transferred into the uteri of pseudopregnant ICR mice. Mice heterozygous for the mutation (Gfap +/-) were obtained by crossing the chimeras to C57BL/6J mice. The heterozygotes (Gfap +/-) were further intercrossed to obtain mutation homozygotes (Gfap/-). The genotypes of the mice were determined by Southern blot analysis of DNA prepared from tails, as mentioned above.
Histological Analysis
For lacZ staining of brain and spinal cord, mice were anesthetized with Nembutal, and brains were fixed by immersion or intracardiac perfusion with fixative solution containing 2% formaldehyde, 2 mM MgCI2, and 1.25 mM EGTA in 0.1 M PIPES (pH 6.9), followed by perfusion with PBS at 4°C. Samples were washed three times in 50 mM phosphate buffer (pH 7.3) and stained at 37°C overnight in a solution containing 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)8, 2 mM MgCI2, 0.02% Nonidet P-40, 0.01% sodium deoxycholate, and 1 mg/ml X-gal (5-bromo-
4-chloro-3-indoyl-[~-D-galactcpyranoside) in the phosphate buffer.
For paraffin sections, fresh samples were fixed with neutral buffered formalin or ethanol, and lacZ-stained samples were postfixed in 2% formaldehyde in the phosphate buffer, dehydrated, and embedded in paraffin. Sections (4 pm) were used for hematoxylin-eosin and immunohistochemical staining.
The immunohistochemical detection was performed with an avidinbiotin-peroxidase technique using the Vectastain ABC kit (Vector Lab.) following the manufacturer's instructions. Anti-GFAP (GF 12.24), anti-vimentin (VIM 3B4), and anti-cytokeratin 8 (Ks 8.7) and 18 (Ks 18.4) monoclonal antibodies were purchased from Progen Biotechnic. Another anti-GFAP monoclonal (6F2) and rabbit anti-GFAP polyclonal antibodies were purchased from Monosan. Monoclonal antibodies to neurofilament 68 kDa, 145 kDa, and 200 kDa subunits were purchased from Transformation Research Inc. Anti-S-100 protein (15E2) and antiactin monoclonal antibodies were purchased from Chemicon International Inc. Anti-vimentin (vg), anti-desmin (DE-U-10), anti-(x-tubulin (DM 1A), anti-CNPase (11-5B), anti-N-CAM (NCAM-OB11), and anti-MAP1 (HM-1) monoclonal antibodies were purchased from Sigma.
Biochemical Analysis
Mouse brain extracts were analyzed by SDS-PAGE (Laemmli, 1970) and immunoblotting. The cerebrum, cerebellum, spinal cord, and optic nerves were homogenized in lysis buffer (50 mM sodium phosphate (pH 7.3), 2 rnM EDTA, 2 mM EGTA, 0.5 rnM TPCK, 0.8 mM phenylmethylsulfonyl fluoride [PMSF]), and an equal volume of 2x SDS-sample buffer (0.25 M Tris-HCI [pH 6.8], 2o/0 SDS, 50o/0 glycerol, 10% 2-mercaptoethanol) was added. Protein (10 pg) was electrophoresed on 10.5% polyacrylamide gels and blotted on an Immobilon-P membrane (Milipore). After blocking the membrane with 5% skim milk in Tris-buffered saline, the blots were immersed sequentially in mouse monoclonal primary antibodies (1:50 to 1:300) and peroxidaseconjugated rat anti-mouse IgG (1:5000; Zymsd Laboratories Inc.) and developed in ECL Western blotting detection reagent (Amersham).
Triton-insoluble cytoskeletal proteins from optic nerve and brain were prepared as described by Pruss et al. (1981) . The tissues were homogenized with ice-cold PBS consisting of 171 mM NaCI, 6 mM sodium phosphate (pH 7.4), 3 mM KCI, 2 mM EDTA, 2 mM EGTA, and 1 mM PMSF. This homogenate was centrifuged at 8000 x g for 10 rain at 4 °C, and the pellet was extracted with an extraction buffer containing 171 mM NaCI, 6 mM sodium phosphate (pH 7.4), 600 mM KCI, 0.5% (w/v) Triton X-100, 1 mM EDTA, 1 mM EGTA, and 1 mM PMSF. This homogenate was centrifuged again at 8000 x g for 10 rain at 4°C, and the pellet was re-extracted twice with the extraction buffer. The final Triton-insoluble pellet was washed four times with ice-cold washing buffer containing 171 mM NaCI, 6 mM sodium phosphate (pH 7.4), and 3 mM KCI.
Inoculation of Scrapie Prion
The Obihiro strain of scrapie prion (PrPSC), which has been passaged in ICR/SIc mice more than ten times (Shinagawa et al. 1985) was prepared from infected brains homogenized in PBS and intracerebrally inoculated (102.8 LDso/animal) into 7-to 8-week-old Gfap -/, Gfap +/-, and Gfap +/+ mice, Normal brain homogenates (10%) were used for mock infection experiments. As a further control, ICR/SIc mice were inoculated with PrP so. Mice were observed daily for the appearance of scrapie-associated symptoms, i,e., ataxia, ruffled hair, disorientation, and depression. Mice were examined histologically and biochemically at 2, 12, 20, and 23 weeks after inoculation.
For biochemical analysis, PrP s: was purified by the procedure of Hilmert and Diringer (1984) with minor modifications to use a bench top ultracentrifuge Beckman Optima TL Briefly, brain samples were homogenized with 10 mM Tris buffer (pH 7.4) containing 10% sarcosyl and then centrifuged at 22,000 x g for 10 min, The supernatant was centrifuged at 540,000 x g for 30 rain. The resulting pellet was sonicated in Tris buffer containing 1% sarcosyl and 10% NaCI and centrifuged again at 540,000 x g for 30 rain. The pellet was treated with proteinase K (2 pg per gram of brain equivalent) at 37°C for 60 rain and centrifuged three times at 22,000 × g for 10 rain. The final pellet was subjected to SDS-PAGE (15% polyacrylamide gel). Immunoblotting was performed using polyclonal anti-prion protein (PrP) antiserum obtained by immunization of rabbit against the synthetic peptide that corresponds to the sequence at amino acids 213-226 (CVTQYQKES-QAYYD) of mouse PrP (Yokoyama et al., unpublished data) .
For the immunohistochemical detection of PrP amyloid plaques, tissue sections were deparaffinized, followed by dehydration and autoclaving (121 °C, 10 rain) in distilled water. Sections were reacted with the above-mentioned primary antibody at a 1:350 dilution and a secondary anti-rabbit IgG using the Vectastain ABC kit.
The infectivity in the brains of infected mice was determined according to a published procedure . Brain samples were homogenized in PBS at 10% or 1% (w/v). Mice were inoculated intracerebrally with 20 p.I of the homogenates. The procedure is based on the correlation between the titer and the incubation period. One of us (T. Y.) has confirmed the reliability of the assay by separate experiments.
